This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Teladoc Stock Rises 59.4% in Three Months: Is This Your Buy Signal?
by Zacks Equity Research
TDOC's use of machine learning and AI continues to drive healthcare innovation.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Will Amazon Bury Hims Stock or Should You Buy the Dip?
by David Bartosiak
Amazon has entered as a rival to Hims business. Did this entry create an opportunity or is Hims stock doomed?
Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?
by Debanjana Dey
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Earnings Estimates Moving Higher for Hims & Hers Health (HIMS): Time to Buy?
by Zacks Equity Research
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Capricor Therapeutics (CAPR) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts
by Zacks Equity Research
Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.
Markets Temper Enthusiasm Ahead of Election Day
by Mark Vickery
We don't expect any sudden movements in the stock market until Wednesday morning the earliest.
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
by Zacks Equity Research
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 0% and 4.52%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
by Zacks Equity Research
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the third quarter.
Hims & Hers Health, Inc. (HIMS) Stock Moves -1.1%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $18.83, denoting a -1.1% change from the preceding trading day.
Nyxoah SA (NYXH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Nyxoah (NYXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
by Zacks Equity Research
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health, Inc. (HIMS) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $21.52, marking a +0.65% move from the previous day.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.36, marking a -1.93% move from the previous day.
FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List
by Zacks Equity Research
The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $18.73, signifying a -0.11% move from its prior day's close.
Hims & Hers Health (HIMS) Soars 10.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
by Zacks Equity Research
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Company News for Oct 4, 2024
by Zacks Equity Research
Companies In the News Are: LEVI, STZ, HIMS, SHEL.
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $18.95, indicating a -1.86% shift from the previous trading day.